Biotech | November 30, 2022
Lonza collaborates with AbTis to extend Bioconjugation capabilities
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Total investment envisaged in this project stands at up to Rs 70 crore
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Subscribe To Our Newsletter & Stay Updated
